Genes
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
85,013 comparisons from ClinicalTrials.gov.
Most participants first33,758 with no events in either group come last2,781 to 2,800 of 85,013
| Comparison | With the outcome | Risk difference, 95% interval | Participants | Trial |
|---|---|---|---|---|
| Pre-ERCP Group vs Post-ERCP Group: Post-ERCP Pancreatitis | 47 of 1,297 100 of 1,303 | -4.1 points -5.9 to -2.3 | 2,600 | NCT02002650 Rectal Indomethacin to Prevent Post-ERCP Pancreatitis |
| Pre-ERCP Group vs Post-ERCP Group: serious adverse events | 15 of 1,297 15 of 1,303 | 0.0 points -0.9 to 0.9 | 2,600 | NCT02002650 Rectal Indomethacin to Prevent Post-ERCP Pancreatitis |
| Zinc vs Placebo: Risk of Treatment Failure. | 267 of 1,300 253 of 1,299 | 1.1 points -2.0 to 4.1 | 2,599 | NCT00148733 CHIZAP: Community- and Health Facility-Based Intervention With Zinc as Adjuvant Therapy for Childhood Pneumonia |
| Administration Prolonged After 12 Weeks vs Administration Not Prolonged After 12 Weeks: Risk Factors for the Proportion of Responders - Prolonged Administration After 12 Weeks. | 39 of 64 1,993 of 2,534 | -17.7 points -30.1 to -6.6 | 2,598 | NCT00772941 Drug Use Investigation Of Varenicline (Regulatory Post Marketing Commitment Plan) |
| Absorb BVS vs XIENCE: Number of Participants With Ischemia Driven TLR (ID-TLR) | 8 of 1,291 1 of 1,304 | 0.5 points 0.1 to 1.1 | 2,595 | NCT02173379 Absorb IV Randomized Controlled Trial |
| Absorb BVS vs XIENCE: Number of Participants Experienced Cardiac Death/All MI | 51 of 1,291 43 of 1,304 | 0.7 points -0.8 to 2.1 | 2,595 | NCT02173379 Absorb IV Randomized Controlled Trial |
| Absorb BVS vs XIENCE: Number of Participants Experienced Death/All MI/All Revascularization (DMR) | 57 of 1,291 46 of 1,304 | 0.9 points -0.6 to 2.4 | 2,595 | NCT02173379 Absorb IV Randomized Controlled Trial |
| Absorb BVS vs XIENCE: Number of Participants Experienced All Death/All MI | 51 of 1,291 43 of 1,304 | 0.7 points -0.8 to 2.1 | 2,595 | NCT02173379 Absorb IV Randomized Controlled Trial |
| Absorb BVS vs XIENCE: Number of Participants With Target Lesion Revascularization (TLR) | 8 of 1,291 1 of 1,304 | 0.5 points 0.1 to 1.1 | 2,595 | NCT02173379 Absorb IV Randomized Controlled Trial |
| Absorb BVS vs XIENCE: Number of Participants Experienced Cardiac Death/All MI/ID-TLR (Major Adverse Cardiac Events-MACE) | 57 of 1,291 44 of 1,304 | 1.0 points -0.5 to 2.6 | 2,595 | NCT02173379 Absorb IV Randomized Controlled Trial |
| Absorb BVS vs XIENCE: Number of Participants With Target Vessel Revascularization (TVR) | 3 of 1,291 0 of 1,304 | 0.2 points -0.1 to 0.7 | 2,595 | NCT02173379 Absorb IV Randomized Controlled Trial |
| Absorb BVS vs XIENCE: Number of Participants Experienced Cardiac Death/All MI/ID-TLR/ID-TVR, Non TL (Target Vessel Failure, TVF) | 57 of 1,291 44 of 1,304 | 1.0 points -0.5 to 2.6 | 2,595 | NCT02173379 Absorb IV Randomized Controlled Trial |
| Absorb BVS vs XIENCE: Number of Participants With All Coronary Revascularization | 10 of 1,291 4 of 1,304 | 0.5 points -0.1 to 1.1 | 2,595 | NCT02173379 Absorb IV Randomized Controlled Trial |
| Absorb BVS vs XIENCE: Number of Participants With Myocardial Infarction (MI) | 50 of 1,291 43 of 1,304 | 0.6 points -0.9 to 2.0 | 2,595 | NCT02173379 Absorb IV Randomized Controlled Trial |
| Absorb BVS vs XIENCE: Number of Participants With ID-TVR Excluding TLR | 3 of 1,291 0 of 1,304 | 0.2 points -0.1 to 0.7 | 2,595 | NCT02173379 Absorb IV Randomized Controlled Trial |
| Absorb BVS vs XIENCE: Number of Participants Experienced Cardiac Death/TV-MI/ID-TLR (TLF) | 57 of 1,291 44 of 1,304 | 1.0 points -0.5 to 2.6 | 2,595 | NCT02173379 Absorb IV Randomized Controlled Trial |
| Absorb BVS vs XIENCE: Number of Participants With Target Vessel Myocardial Infarction (TV-MI) | 50 of 1,291 43 of 1,304 | 0.6 points -0.9 to 2.0 | 2,595 | NCT02173379 Absorb IV Randomized Controlled Trial |
| Absorb BVS vs XIENCE: Number of Death (Cardiac, Vascular, Non-cardiovascular) | 1 of 1,291 0 of 1,304 | 0.1 points -0.2 to 0.4 | 2,595 | NCT02173379 Absorb IV Randomized Controlled Trial |
| ATP and Shock vs Shock Only: Appropriate Shock | 96 of 1,302 132 of 1,293 | -2.8 points -5.0 to -0.7 | 2,595 | NCT02923726 Assessment of Primary Prevention Patients Receiving An ICD - Systematic Evaluation of ATP |
| ATP and Shock vs Shock Only: Inappropriate Shock | 40 of 1,302 62 of 1,293 | -1.7 points -3.3 to -0.2 | 2,595 | NCT02923726 Assessment of Primary Prevention Patients Receiving An ICD - Systematic Evaluation of ATP |
Code
curl "https://conductscience.org/api/comparisons/v1?page=140"
Response
The first 2 of this page's 20 results. GET /api/comparisons/v1?page=140
{
"data": {
"total": 85013,
"results": [
{
"id": "NCT02002650-8a96801e",
"title": "Pre-ERCP Group vs Post-ERCP Group: Post-ERCP Pancreatitis",
"summary": "47 of 1297 against 100 of 1303; risk difference -4.1 points, 95% interval -5.9 to -2.3; NCT02002650, Rectal Indomethacin to Prevent Post-ERCP Pancreatitis",
"record": "/library/comparisons/NCT02002650-8a96801e",
"nct_id": "NCT02002650",
"kind": "outcome",
"participants": 2600,
"risk_difference": {
"value": -0.04050849974940694,
"lower": -0.058570561782453734,
"upper": -0.022893582829698434
},
"group_1": "47 of 1,297",
"group_2": "100 of 1,303",
"difference": "-4.1 points",
"interval": "-5.9 to -2.3",
"trial_title": "Rectal Indomethacin to Prevent Post-ERCP Pancreatitis"
},
{
"id": "NCT02002650-sae",
"title": "Pre-ERCP Group vs Post-ERCP Group: serious adverse events",
"summary": "15 of 1297 against 15 of 1303; risk difference 0.0 points, 95% interval -0.9 to 0.9; NCT02002650, Rectal Indomethacin to Prevent Post-ERCP Pancreatitis",
"record": "/library/comparisons/NCT02002650-sae",
"nct_id": "NCT02002650",
"kind": "serious-adverse-events",
"participants": 2600,
"risk_difference": {
"value": 0.00005325472147484772,
"lower": -0.00862636943007026,
"upper": 0.008750823522567418
},
"group_1": "15 of 1,297",
"group_2": "15 of 1,303",
"difference": "0.0 points",
"interval": "-0.9 to 0.9",
"trial_title": "Rectal Indomethacin to Prevent Post-ERCP Pancreatitis"
}
],
"no_events": 33758,
"columns": [
{
"key": "title",
"label": "Comparison"
},
{
"key": "group_1",
"label": "With the outcome",
"under": "group_2"
},
{
"key": "difference",
"label": "Risk difference, 95% interval",
"under": "interval"
},
{
"key": "participants",
"label": "Participants"
},
{
"key": "nct_id",
"label": "Trial",
"under": "trial_title"
}
],
"order": "Most participants first",
"kinds": {
"all": 85013,
"outcome": 33568,
"serious-adverse-events": 31897,
"deaths": 19548
}
},
"release": "trial-comparisons-2026-03-23-0.1.0",
"terms": [
{
"source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
"license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "Freely available. Acknowledgement requested"
},
{
"source": "ClinicalTrials.gov",
"license": "none stated",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "No license stated"
}
],
"next": "/api/comparisons/v1?page=141",
"request_id": "MG9NdcfV4DdxLZAJ"
}Ask about these results. The first 10 go in the prompt.
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
ClinicalTrials.gov
Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.
Patent publications
Paste a sequence and see the patents that disclose it.
Opens sequences.conductscience.org
For software
Every answer on this page is also JSON, under /api/comparisons/v1. No key.
GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome
Ask an assistant